Romiplostim API is a recombinant protein therapeutic belonging to the thrombopoietin receptor agonist class. It is a genetically engineered Fc-peptide fusion protein, also known as a peptibody, designed to stimulate platelet production through activation of the thrombopoietin receptor.
Romiplostim is produced using recombinant DNA technology in Escherichia coli. The molecule contains a human IgG1 Fc domain linked to peptide sequences that contain two thrombopoietin-receptor-binding domains.
Romiplostim is identified by CAS 267639-76-9 and FDA UNII GN5XU2DXKV. FDA GSRS classifies it as a protein and reports an estimated average molecular weight of approximately 59,100 Da.
Unlike endogenous thrombopoietin, romiplostim does not have amino-acid sequence homology with human thrombopoietin. Its engineered structure allows it to bind and activate the thrombopoietin receptor, resulting in increased megakaryocyte maturation and platelet production.
Romiplostim is a dimeric fusion protein consisting of two identical single-chain subunits. Each subunit contains 269 amino acids and combines an IgG1 Fc region with a peptide portion containing two thrombopoietin-receptor-binding domains.
Because it is a recombinant protein rather than a conventional organic small molecule, its quality profile is defined primarily through protein identity, purity, aggregation, biological activity, protein concentration and process-related impurities.
Romiplostim is used as a thrombopoietin receptor agonist for increasing platelet production. The currently authorized medicine Nplate is indicated for primary immune thrombocytopenia (ITP), including chronic primary ITP in pediatric patients aged one year and older in the EU.
Romiplostim activates the thrombopoietin receptor and stimulates megakaryocyte development, thereby increasing platelet production.
Quality control of Romiplostim API requires a biologics-oriented analytical strategy. Regulatory assessment has included structural and biophysical characterization using techniques such as UV spectroscopy, circular dichroism, FTIR, fluorescence and differential scanning calorimetry. Biological activity is also an important release characteristic.
Protein identity and purity can be evaluated through peptide/protein-specific analytical methods, while aggregation and molecular-size variants can be assessed using chromatographic techniques such as size-exclusion HPLC. Charge variants can be characterized by cation-exchange chromatography, and biological activity is evaluated using a validated potency assay.
Manufacturing Romiplostim requires recombinant biotechnology processes, controlled fermentation and purification, followed by extensive characterization of the resulting protein.
Important quality attributes include identity, purity, potency, protein concentration, aggregation, charge variants, process-related impurities and microbial quality. Regulatory assessment confirms that the active substance is routinely controlled using chemical-physical and biological tests covering appearance, pH, identity, purity, potency, quantity and microbial content.
Romiplostim drug substance and finished product require controlled storage conditions appropriate for a recombinant protein.
For the marketed Nplate finished product, the EMA-supported storage condition is 2°C to 8°C, with protection from light and no freezing. These are finished-product conditions and should not automatically be represented as the API drug-substance storage specification.
Typical documentation for Romiplostim API may include:
Romiplostim is a well-characterized recombinant thrombopoietin receptor agonist with an established protein structure, biological mechanism and analytical control strategy. Its quality assessment requires biologic-specific characterization rather than conventional small-molecule API testing.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |